Login / Signup

Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation.

Sylvie PerreaultRobert CôtéAlice DragomirBrian White-GuayAurélie LengletMarc Dorais
Published in: PloS one (2022)
No significant differences were observed in the effectiveness or safety outcome between low-dose and standard-dose rivaroxaban, except for AMI. However, low-dose apixaban was associated with a greater risk of stroke/SE and death without a reduction in the bleeding rates.
Keyphrases
  • low dose
  • atrial fibrillation
  • venous thromboembolism
  • high dose
  • heart failure
  • randomized controlled trial
  • percutaneous coronary intervention
  • acute myocardial infarction
  • systematic review